What Role Can Pharmacists Play in Managing Patients with CV Disease?

A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.

Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.

fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.

A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.

In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg vs placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.

Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.

Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.

Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.